Community Practice Connections™: Top 10 Oncogenic Markers in Advanced NSCLC: What You Need to Know About Testing, Trials, and Novel Therapies

Release Date: July 28, 2021
Expiration Date: July 28, 2022

Activity Overview

The ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including those targeting c-MET, ALK, ROS1, EGFR, RET, HER2/3, TRK (NTRK), KRAS, BRAF, TROP2 and PARP.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the live webcast satellite symposium held in conjunction with the 2021 ASCO Annual Meeting, held in June 2021. This unique and engaging multimedia activity is ideal for the community-based clinician, focusing on the strategies to improve the application and interpretation of testing in NSCLC to identify actionable alterations, in addition to the latest data on the safety and efficacy of emerging targeted therapies. The program is designed to educate those who did not attend the live meeting and to reinforce the learning for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen, AstraZeneca, Daiichi Sankyo, Inc., Genentech, Inc., Illumina, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc.

Target Audience

This educational program is directed toward the American Society of Clinical Oncology (ASCO) audience, including medical oncologists, pathologists, and pulmonologists interested in the treatment of advanced NSCLC. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and those involved in the treatment of patients with advanced NSCLC, are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline current and emerging molecular biomarkers that facilitate treatment personalization in NSCLC
• Describe current and evolving testing strategies for biomarker detection in patients with NSCLC
• Review recent clinical trial data and strategies for integrating current and recently approved targeted therapies into clinical practice for the treatment of patients with advanced NSCLC
• Assess the implications of emerging targets, therapies, and strategies in the treatment of patients with advanced NSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: MacroGenics, Merck, AstraZeneca; Consultant: Genentech, Eli Lilly, Celgene, AstraZene-ca, Blueprint, Daiichi Sankyo.

Paul A. Bunn, Jr, MD
Distinguished Professor, James Dudley Chair in Cancer Research University of Colorado Denver School of Medicine
Division of Medical Oncology
Aurora, CO

Disclosures: Consultant: Ascentage, AstraZeneca, CStone, Genentech.

Justin F. Gainor, MD
Director, Center for Thoracic Cancers Director of Targeted Immunotherapy Massachusetts General Hospital Assistant Professor
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Novartis, Takeda, Genentech/Roche, BMS, Tesaro, Moderna, Blueprint, Jounce, Array Bio-Pharma, Merck, AstraZeneca, Adaptimmune, Novartis, Alexo; Consultant: Novartis, Takeda, Genentech/Roche, BMS, Tesaro, Moderna, Blueprint, Jounce, Array Bio-Pharma, Merck, AstraZeneca, Adaptimmune, Novartis, Alexo; Other: Immediate faculty member who is an employee and owns stock in Ironwood Pharmaceuticals.

Rebecca S. Heist, MD
Associate Professor, Harvard Medical School
Associate Professor in Medicine, MGH Cancer Center, Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: To institution, not to self: Novartis, Daichii Sankyo, Mirati, Turning Point, Agios, Abbvie, Corvus, Exelixis, Lilly; Consultant: Daichii Sankyo, Novartis, EMD Serono.

Lynette M. Sholl, MD
Associate Professor, Pathology Harvard Medical School
Associate Pathologist, Pathology Brigham And Women’s Hospital Dana-Farber/Harvard Cancer Center
Boston, MA

Disclosures: Grant Research Support: Roche; Consultant: EMD Serono, AstraZeneca; Shareholder: Moderna.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.